| Filed On | Filing |
|---|---|
| 28 Sep 2026 | ARS |
| 28 Sep 2026 | Proxy statement: annual meeting on November 4, 2026 |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
A New Approach to Inflammatory Diseases NASDAQ: GRI | gribio.com CORPORATE PRESENTATION SEPT 2026 Exhibit 99.1 |
| 14 Aug 2026 | 10-Q |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 18 Jun 2026 | 8-K: Other Events |
| 14 May 2026 | 8-K: Results of Operations and Financial Condition; Other Events |
| 13 May 2026 | SCHEDULE 13G/A |
| 13 May 2026 | 10-Q |
| 13 Feb 2026 | SCHEDULE 13G/A |
| 10 Feb 2026 | SCHEDULE 13G/A |
| 04 Feb 2026 | 8-K: Results of Operations and Financial Condition |
| 30 Jan 2026 | CORRESP |
| 30 Jan 2026 | UPLOAD |
| 30 Jan 2026 | EFFECT |
| 30 Jan 2026 | 10-K |
| 30 Jan 2026 | 424B5 |
| 30 Jan 2026 | S-3 |
| 30 Jan 2026 | S-8 |
| 30 Jan 2026 | 8-K: Entry into a Material Definitive Agreement |
Loading...
